Table 2.
Comparisons of heterologous versus homologous regimens
| Ad26.COV2-S | BNT162b2 | ChAdOx1 nCoV-19 | CoronaVac | p value* | ||
|---|---|---|---|---|---|---|
| Anti-spike IgG by multiplex immunoassay | ||||||
| All participants | ||||||
| Number of participants | 294 | 333 | 296 | 281 | ·· | |
| Geometric mean ratio | 6·7 (5·8–7·7)† | 13·4 (11·6–15·3)† | 7·0 (6·1–8·1)† | ref | <0·0001 | |
| 18–60 years | ||||||
| Number of participants | 152 | 165 | 150 | 148 | ·· | |
| Geometric mean ratio | 6·1 (5·1–7·2) | 12·1 (10·3–14·2) | 6·4 (5·5–7·6) | ref | ·· | |
| 61 years and over | ||||||
| Number of participants | 142 | 168 | 146 | 133 | ·· | |
| Geometric mean ratio | 7·3 (5·8–9·2) | 15·0 (12·0–18·6) | 7·6 (6·1–9·5) | ref | ·· | |
| Pseudovirus neutralisation titres | ||||||
| All participants | ||||||
| Number of participants | 47 | 49 | 52 | 46 | ·· | |
| Geometric mean ratio | 8·7 (5·9–12·9) | 21·5 (14·5–31·9) | 10·6 (7·2–15·6) | ref | <0·0001 | |
| 18–60 years | ||||||
| Number of participants | 22 | 23 | 26 | 22 | ·· | |
| Geometric mean ratio | 7·2 (4·5–11·4) | 15·6 (9·8–24·7) | 8·2 (5·2–12·9) | ref | ·· | |
| 61 years and over | ||||||
| Number of participants | 25 | 26 | 26 | 24 | ·· | |
| Geometric mean ratio | 10·5 (5·6–19·5) | 30·7 (16·5–57·1) | 14·2 (7·6–26·5) | ref | ·· | |
Data are the geometric mean ratio of heterologous versus homologous (95% CI), unless otherwise specified.
*
p value from ANOVA model comparing log-geometric means across all four groups.
†
p value <0·0001, values from superiority comparisons comparing heterologous schedules to homologous schedules.